p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy
Mario Morales-Martínez1, Mario I Vega1,2
1Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City 06720, Mexico.
Abstract:
Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.
Insights
p38 mitogen-activated protein kinase (p38) signaling drives cancer treatment resistance and progression. Targeting p38 may reverse resistance and prevent disease advancement in multiple myeloma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- Therapy resistance and disease progression are primary causes of cancer mortality.
- Signaling pathways are critical mediators of treatment resistance and cancer progression.
- Multiple myeloma exhibits resistance to various cancer therapies.
Purpose of the Study:
- To review recent findings on the role of p38 mitogen-activated protein kinase (p38) in multiple myeloma.
- To explore p38's expression, activity, and isoforms in the context of cancer resistance.
- To discuss the potential clinical utility of targeting p38 for overcoming treatment resistance and preventing progression.
Main Methods:
- Literature review of recent research on p38 signaling in multiple myeloma.
- Analysis of studies investigating p38 expression and activity.
- Examination of data on p38 isoforms and their role in resistance mechanisms.
Main Results:
- p38 signaling pathways are implicated in resistance to chemotherapy, radiotherapy, and immunotherapy.
- Recent advances have improved understanding of p38's role in multiple myeloma progression.
- p38 activity and isoforms are key factors in treatment resistance.
Conclusions:
- p38 signaling is a significant contributor to treatment resistance and progression in multiple myeloma.
- Therapeutic strategies targeting p38 show promise for reversing chemotherapy resistance.
- Further investigation into p38's clinical role is warranted for improved multiple myeloma treatment.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...